SO
OVID icon

STRS Ohio’s Ovid Therapeutics OVID Stock Holding History

STRS Ohio’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,600
Closed -$94K – 2367
2021
Q1 		$94K Hold
23,600
– – ﹤0.01% 1956
2020
Q4 		$54K Buy
23,600
+4,000
+20% +$18.6K ﹤0.01% 1983
2020
Q3 		$112K Buy
19,600
+6,800
+53% +$45.5K ﹤0.01% 1823
2020
Q2 		$94K Buy
+12,800
New +$59.9K ﹤0.01% 1804
2019
Q2 		– Sell
-11,000
Closed -$19.6K – 2179
2019
Q1 		$19K Hold
11,000
– – ﹤0.01% 1971
2018
Q4 		$26K Hold
11,000
– – ﹤0.01% 1967
2018
Q3 		$62K Hold
11,000
– – ﹤0.01% 1921
2018
Q2 		$85K Buy
11,000
+7,500
+214% +$64.4K ﹤0.01% 1896
2018
Q1 		$24K Buy
3,500
+2,000
+133% +$16.2K ﹤0.01% 1808
2017
Q4 		$14K Hold
1,500
– – ﹤0.01% 1836
2017
Q3 		$12K Hold
1,500
– – ﹤0.01% 1885
2017
Q2 		$15K Buy
+1,500
New +$19.6K ﹤0.01% 1890

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

STRS Ohio's OVID Position: Q2 2021 in Review

STRS Ohio sold out of Ovid Therapeutics (OVID) in Q2 2021, closing a stake of 23,600 shares — an estimated $94K sold.

STRS Ohio first reported a position in OVID in Q2 2017 and held it in 12 quarters. The position peaked at $112K in Q3 2020. 80 funds tracked by Wall St. Rank hold OVID as of Q2 2021.

  • STRS Ohio reported no remaining Ovid Therapeutics position as of Q2 2021 after selling out during the quarter.
  • STRS Ohio sold 23,600 Ovid Therapeutics shares in Q2 2021, an estimated $94K.
  • STRS Ohio first reported a position in Ovid Therapeutics in Q2 2017 and held it in 12 quarters.
  • STRS Ohio's Ovid Therapeutics position peaked at $112K in Q3 2020.
  • 80 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2021.

Based on STRS Ohio's 13F filing for Q2 2021, filed 26 Jul 2021.